Beyond substance abuse, behavioral addictions are also a major problem in society. We went to addiction-specialist, Awakn Life Sciences to learn more these additional treatment markets.
Exploring the companies and themes that make up this emerging and exciting new sector
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
atai launches Invyxis, as a new company devoted to the creation of novel psychedelics molecules.
Novamind Announces Closing of CAD$5 Million Private Placement with Institutional Investor
Novamind announces the closing of its previously announced CAD$5 million private placement.
Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans
Mydecine announces a partnership with Combat Stress and King's College London to provide psychoactive-assisted therapy for PTSD.
Novamind Announces CAD$5 Million Private Placement with Institutional Investor
Novamind announces a CAD$5 million placement with a single institutional investor. Units are priced at CAD$0.40 with a full warrant at CAD$0.50.
Momentum Building For U.S. Psychedelics Legal Reform
Sudden indications of a regulatory thaw in the U.S. toward psychedelic medicine bode well for psychedelic stocks in 2022.
Numinus Wellness Inc. Reports Q1 2022 Results
Numinus Wellness reports Q1 2022 results, including quarterly revenues of CAD$0.8 million and a gross profit of CAD$50,965.
Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II
Eleusis, a private psychedelics company, has announced it is going public via a merger with Silver Spike Acquisition Corp II.
Awakn Life Sciences Signs MOU with Maps
Awakn and MAPS to team up to address Alcohol Use Disorder in Europe.
Levitee Labs Announces Non-Brokered Private Placement of up to $3,000,000
Levitee Labs announces a CAD$3 million private placement with units priced at CAD$0.20 and a full warrant at CAD$0.40.
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial
Numinus announces all regulatory authorization and preparations have been completed for the next stage of MAPS' clinical trial for MDMA-assisted psychotherapy.
Study Finds 65% Of Americans With Mental Health Conditions Want Access To Psychedelics
A new study conducted by The Harris Poll and Delic Holdings Corp found that 65% of affected Americans want access to psychedelics for mental health.